rocbrutinib   Click here for help

GtoPdb Ligand ID: 12875

Synonyms: LP-168 | LP168
Approved drug Immunopharmacology Ligand
rocbrutinib is an approved drug
Compound class: Synthetic organic
Comment: The structure for rocbrutinib was obtained from proposed INN list 129 (August 2023) where it is described as Bruton's tyrosine kinase inhibitor and antineoplastic agent. It is one of the compounds claimed in patent WO2019161152A1 (Newave Pharmaceutical) [1]. LP-168 is the one lead in Newave's development pipeline that fits the profile of a potential BTK inhibitor. Code name-to-INN was formally disclosed in 2024 [3]. Rocbrutinib binds covalently to wild-type BTK and non-covalently to mutated BTK proteins, including BTKC481 and gatekeeper mutations.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 14
Hydrogen bond donors 3
Rotatable bonds 10
Topological polar surface area 145.65
Molecular weight 761.91
XLogP 2.18
No. Lipinski's rules broken 2

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C=CC(=O)NC1=CC(=CC=C1N2CCN(C[C@]2([H])C)C3CCOCC3)NC4=NC(=CN(C)C4=O)C5=C(CO)C(=NC=C5)N6CCN7C(=CC8=C7CC(C)(C)C8)C6=O
Isomeric SMILES [H][C@]1(C)CN(CCN1C2=CC=C(NC3=NC(=CN(C)C3=O)C4=C(CO)C(=NC=C4)N5CCN6C7=C(CC(C)(C)C7)C=C6C5=O)C=C2NC(=O)C=C)C8CCOCC8
InChI InChI=1S/C42H51N9O5/c1-6-37(53)45-32-20-28(7-8-34(32)49-14-13-48(23-26(49)2)29-10-17-56-18-11-29)44-38-41(55)47(5)24-33(46-38)30-9-12-43-39(31(30)25-52)51-16-15-50-35(40(51)54)19-27-21-42(3,4)22-36(27)50/h6-9,12,19-20,24,26,29,52H,1,10-11,13-18,21-23,25H2,2-5H3,(H,44,46)(H,45,53)/t26-/m0/s1
InChI Key OYJVFTNYBWVQHA-SANMLTNESA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Rocbrutinib (LP-168) was advanced to clinical assessment for potential to treat B cell malignancies. First approval was granted by China's NMPA in June 2026 [2], to treat BTKC481S mutant positive relapsed/refractory CLL/SLL.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05917964 A Food Effect Study of LP-168 Tablets in Healthy Subjects Phase 1 Interventional Guangzhou Lupeng Pharmaceutical Company LTD.
NCT04993690 A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma Phase 1 Interventional Guangzhou Lupeng Pharmaceutical Company LTD.
NCT05716087 A Study of LP-168 in Participants With Relapse or Refractory Mantle Cell Lymphoma Phase 2 Interventional Guangzhou Lupeng Pharmaceutical Company LTD.